<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03100448</url>
  </required_header>
  <id_info>
    <org_study_id>T-190</org_study_id>
    <nct_id>NCT03100448</nct_id>
  </id_info>
  <brief_title>A 1-year Clinical Investigation on the On1 Concept</brief_title>
  <acronym>T-190</acronym>
  <official_title>An Open, Prospective, Multi-center Study Evaluating the On1 Concept on NobelActive Implants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nobel Biocare</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nobel Biocare</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A 1-year Clinical Investigation on the On1 Concept.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This open, prospective, multi-center clinical trial evaluates the On1 Concept for the&#xD;
      treatment of patients in need for single tooth replacement or 3-unit bridges in the mandible&#xD;
      or maxilla.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 24, 2017</start_date>
  <completion_date type="Actual">May 8, 2019</completion_date>
  <primary_completion_date type="Actual">May 8, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Marginal bone remodeling</measure>
    <time_frame>12 months</time_frame>
    <description>The change in the marginal bone level around the implants from baseline to 12-months of follow-up is measured on paired radiographs.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Soft tissue outcome (soft tissue height)</measure>
    <time_frame>12 months</time_frame>
    <description>The change in soft tissue height from baseline to 12-months of follow-up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Component Survival</measure>
    <time_frame>12 months</time_frame>
    <description>Survival rates of implants as well as On1 components and prosthetics.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Component Success</measure>
    <time_frame>12 months</time_frame>
    <description>Success of implants as well as On1 components and prosthetics by clinical evaluation calculated in a cumulative success rate life table.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient's pain perception (visual analogue score)</measure>
    <time_frame>3 months</time_frame>
    <description>The patient's pain perception during the post surgery period is evaluated by the use of a visual analogue score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient's oral health related quality of life (OHIP-14)</measure>
    <time_frame>12 months</time_frame>
    <description>The patient's oral health related quality of life is evaluated by the use of the OHIP-14 questionnaire.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient's satisfaction with function &amp; esthetics (visual analogue score)</measure>
    <time_frame>12 months</time_frame>
    <description>The patient's satisfaction with function &amp; esthetics is evaluated by the use of a visual analogue score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ease of use of the On1 Concept (questionnaire)</measure>
    <time_frame>12 months</time_frame>
    <description>The ease of use of the On1 Concept is evaluated by the use of a surgeon questionnaire.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">72</enrollment>
  <condition>Implant</condition>
  <arm_group>
    <arm_group_label>On1 Concept</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>On1 Concept &amp; NobelActive implants</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>On1 Concept</intervention_name>
    <description>NobelActive implant placement with simultaneous On1 Base placement</description>
    <arm_group_label>On1 Concept</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  The subject is at least 18 years of age (or age of consent) and has passed cessation&#xD;
             of growth.&#xD;
&#xD;
          -  Obtained informed consent from the subject.&#xD;
&#xD;
          -  The patient is willing and able to comply with all study related procedures (such as&#xD;
             exercising oral hygiene and attending all follow-up procedures).&#xD;
&#xD;
          -  The subject shall be healthy and compliant with good oral hygiene.&#xD;
&#xD;
          -  Full-mouth bleeding score (FMBS) lower than 25% [10].&#xD;
&#xD;
          -  Full-mouth plaque score (FMPI) lower than 20% [11].&#xD;
&#xD;
          -  Suitable for implant treatment in the posterior, pre-molar and canine area in the&#xD;
             mandible or maxilla.&#xD;
&#xD;
          -  The subject shall have a favorable and stable occlusal relationship.&#xD;
&#xD;
          -  In need of one or multiple single tooth replacements or 3-unit bridges.&#xD;
&#xD;
          -  Healed sites in need for implant placement (i.e. minimum of 6 weeks post extraction).&#xD;
&#xD;
          -  The implant sites are free from infection and extraction remnants.&#xD;
&#xD;
          -  The subject is suitable for a 1-stage surgical procedure.&#xD;
&#xD;
          -  Sufficient amount of buccal and lingual keratinized mucosa.&#xD;
&#xD;
          -  The subject has a sufficient amount of bone for placing NobelActive implants with a&#xD;
             length of at least 8 mm.&#xD;
&#xD;
          -  Primary implant stability as assessed by manual hand testing.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  The subject is not able to give her/his informed consent of participating.&#xD;
&#xD;
          -  Health conditions, which do not permit the surgical (including anesthesia) or&#xD;
             restorative procedure.&#xD;
&#xD;
          -  Reason to believe that the treatment might have a negative effect on the subject's&#xD;
             overall situation (psychiatric problems), as noted in subject records or in subject&#xD;
             history.&#xD;
&#xD;
          -  Any disorders in the planned implant area such as previous tumors, chronic bone&#xD;
             disease or previous irradiation in the head/neck area.&#xD;
&#xD;
          -  Infections in the planned implantation site or adjacent tissue.&#xD;
&#xD;
          -  Acute, untreated periodontitis in the planned implantation site or adjacent tissue.&#xD;
&#xD;
          -  Any ongoing application of interfering medication (steroid therapy, bisphosphonate,&#xD;
             etc.).&#xD;
&#xD;
          -  Uncontrolled diabetes, i.e. a subject with diagnosed diabetes that has a history of&#xD;
             neglecting doctor's recommendations regarding treatment, food and alcohol intake or&#xD;
             A1c level above 8%.&#xD;
&#xD;
          -  Alcohol or drug abuse as noted in subject records or in subject history.&#xD;
&#xD;
          -  Smoking of &gt;10 cigarettes/day.&#xD;
&#xD;
          -  Fresh extraction sites (up to 6 weeks).&#xD;
&#xD;
          -  Severe bruxism or other destructive habits.&#xD;
&#xD;
          -  Pregnant or lactating women at the time of implant insertion.&#xD;
&#xD;
          -  Previous bone augmentation (lateral and/or vertical).&#xD;
&#xD;
          -  Soft tissue augmentation less than 2 months before implant placement.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alina Gologan, DMD</last_name>
    <role>Study Director</role>
    <affiliation>Nobel Bioacare</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Service de MÃ©decine dentaire CHU Sart Tilman</name>
      <address>
        <city>Liege</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Studio Odontoiatrico Specialistico</name>
      <address>
        <city>Cattolica</city>
        <zip>47841</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dental Clinic Auksteja</name>
      <address>
        <city>Kaunas</city>
        <state>LT</state>
        <zip>44275</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dental Clinic Auksteja</name>
      <address>
        <city>Kaunas</city>
        <zip>44275</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vilnius Implantology Center</name>
      <address>
        <city>Vilnius</city>
        <zip>01205</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tandartspraktijk Staas &amp; Bergmans</name>
      <address>
        <city>Hertogenbosch</city>
        <zip>5216</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Italy</country>
    <country>Lithuania</country>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>February 28, 2017</study_first_submitted>
  <study_first_submitted_qc>March 29, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 4, 2017</study_first_posted>
  <last_update_submitted>January 29, 2021</last_update_submitted>
  <last_update_submitted_qc>January 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

